Leerink Partners Maintains Outperform on Mereo BioPharma Group, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners maintains an Outperform rating on Mereo BioPharma Group (NASDAQ:MREO) and raises the price target from $6 to $8.
June 20, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has maintained its Outperform rating on Mereo BioPharma Group and raised the price target from $6 to $8, indicating increased confidence in the company's future performance.
The raised price target from $6 to $8 by Leerink Partners suggests a positive outlook on Mereo BioPharma Group's future performance. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100